J. Lemonnier

发表

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

J. Lemonnier, F. Bidard, J. Pierga, 2019, Angiogenesis.

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions

C Beauvillain, J. Lemonnier, J. Grob, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Activation of p38 Mitogen‐Activated Protein Kinase and c‐Jun‐NH2‐Terminal Kinase by BMP‐2 and Their Implication in the Stimulation of Osteoblastic Cell Differentiation

J. Lemonnier, G. Palmer, J. Guicheux, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

F. Bertucci, J. Lemonnier, J. Bonneterre, 2016, The Lancet. Oncology.

Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation*

J. Lemonnier, P. Marie, J. Caverzasio, 2004, Journal of Biological Chemistry.

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

G. MacGrogan, S. Mathoulin-Pélissier, J. Lemonnier, 2020, British Journal of Cancer.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin-1.

J. Lemonnier, O. Fromigué, P. Marie, 2001, The American journal of pathology.

Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.

A. Vincent-Salomon, J. Lemonnier, M. Mouret-Reynier, 2022, European journal of cancer.

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

M. Mathieu, J. Lemonnier, V. Bécette, 2016, Cancer.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

F. Bertucci, F. André, J. Lemonnier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2011, Familial Cancer.

Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

F. André, J. Lemonnier, J. Bonneterre, 2015 .

Tumor in ﬁ ltrating lymphocyte strati ﬁ cation of prognostic staging of early-stage triple negative breast cancer

R. Gray, C. Sotiriou, S. Loi, 2021 .

LBA9Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

A. Vincent-Salomon, J. Lemonnier, J. Canon, 2017 .

Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

I. Bièche, F. Clatot, J. Lemonnier, 2020 .

Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome.

A. Munnich, J. Lemonnier, P. Marie, 1998, The Journal of clinical investigation.

Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -beta-catenin-independent signaling pathway.

F. Mascarelli, J. Lemonnier, P. Marie, 2004, Experimental cell research.

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

I. Bièche, F. Clatot, F. André, 2022, The Lancet. Oncology.

The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation.

J. Lemonnier, P. Marie, P. Delannoy, 2000, Experimental cell research.

Increased expression of protein kinase Calpha, interleukin-1alpha, and RhoA guanosine 5'-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray.

J. Lemonnier, P. Marie, P. Delannoy, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study

F. André, J. Lemonnier, C. Coutant, 2019, PLoS medicine.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment

J. Lemonnier, M. Campone, O. Coqueret, 2019, Cell Death & Disease.

SHARE: a French multicenter phase III trial comparing accelerated partial irradiation versus standard or hypofractionated whole breast irradiation in breast cancer patients at low risk of local recurrence.

I. Dumas, J. Lemonnier, C. Bourgier, 2013, Clinical advances in hematology & oncology : H&O.

N‐ and E‐cadherin mediate early human calvaria osteoblast differentiation promoted by bone morphogenetic protein‐2

J. Lemonnier, P. Marie, E. Haÿ, 2000 .

N- and E-cadherin mediate early human calvaria osteoblast differentiation promoted by bone morphogenetic protein-2.

J. Lemonnier, P. Marie, E. Haÿ, 2000, Journal of cellular physiology.

Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

S. Shak, F. Baehner, F. Penault-Llorca, 2014 .

Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides

P. Courtiol, M. Sefta, D. Drubay, 2022, bioRxiv.

Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides

P. Courtiol, M. Sefta, D. Drubay, 2022, bioRxiv.

Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway*

J. Lemonnier, O. Fromigué, P. Marie, 2001, The Journal of Biological Chemistry.

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2015, Future oncology.

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Heikki Joensuu, Carsten Denkert, Damien Drubay, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer

J. Lemonnier, F. Bidard, J. Pierga, 2021, NPJ breast cancer.

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.

J. Lemonnier, M. Campone, J. Canon, 2019, European journal of cancer.

TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing

J. Lemonnier, N. Sevenet, D. Stoppa-Lyonnet, 2021, Cancers.

Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies

S. Michiels, F. André, J. Lemonnier, 2019, Breast Cancer Research and Treatment.

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

I. Bièche, F. Clatot, F. André, 2022, BMJ Open.

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response

J. Lemonnier, V. Bécette, P. Chérel, 2020, Cancer Imaging.

Protein Kinase C-independent Activation of Protein Kinase D Is Involved in BMP-2-induced Activation of Stress Mitogen-activated Protein Kinases JNK and p38 and Osteoblastic Cell Differentiation*

J. Lemonnier, J. Guicheux, C. Ghayor, 2004, Journal of Biological Chemistry.

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications

J. Lemonnier, M. Campone, J. Canon, 2019, Breast Cancer Research.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

A. Vincent-Salomon, J. Lemonnier, J. Canon, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Bone Morphogenetic Protein Receptor IB Signaling Mediates Apoptosis Independently of Differentiation in Osteoblastic Cells*

J. Lemonnier, O. Fromigué, P. Marie, 2004, Journal of Biological Chemistry.

Protein kinase C-dependent upregulation of N-cadherin expression by phorbol ester in human calvaria osteoblasts.

J. Lemonnier, P. Marie, P. Delannoy, 2001, Experimental cell research.

Role of N‐Cadherin and Protein Kinase C in Osteoblast Gene Activation Induced by the S252W Fibroblast Growth Factor Receptor 2 Mutation in Apert Craniosynostosis

J. Lemonnier, P. Marie, P. Delannoy, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increased Expression of Protein Kinase Cα, Interleukin‐1α, and RhoA Guanosine 5′‐Triphosphatase in Osteoblasts Expressing the Ser252Trp Fibroblast Growth Factor 2 Apert Mutation: Identification by Analysis of Complementary DNA Microarray

J. Lemonnier, P. Marie, P. Delannoy, 2001 .

Fibroblast growth factor‐2 (FGF‐2) increases N‐cadherin expression through protein kinase C and Src‐kinase pathways in human calvaria osteoblasts

J. Lemonnier, P. Marie, P. Delannoy, 2001, Journal of cellular biochemistry.

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

J. Lemonnier, B. Asselain, M. Campone, 2017, European journal of cancer.

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

J. Lemonnier, M. Campone, D. Cameron, 2021 .

Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)

F. André, J. Lemonnier, S. Dauchy, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

F. Penault-Llorca, J. Lemonnier, J. Canon, 2013, Breast Cancer Research and Treatment.

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207).

J. Lemonnier, B. Thürlimann, H. Hawle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

J. Lemonnier, V. Bécette, M. Mouret-Reynier, 2018, Journal of Hematology & Oncology.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

H. Wildiers, J. Lemonnier, M. Lacroix-Triki, 2018, European journal of cancer.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

M. Espié, D. Cox, R. Rouzier, 2016, Bulletin du cancer.

Body weight and return to work among survivors of early-stage breast cancer

S. Michiels, F. André, J. Lemonnier, 2020, ESMO Open.

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2023, Breast Cancer Research and Treatment.

J. Lemonnier, G. Romieu, J. Pierga, 2020, Pharmaceuticals.

Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.

J. Lemonnier, M. Lacroix-Triki, H. Bonnefoi, 2022, Journal of Clinical Oncology.

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

R. Gray, C. Sotiriou, S. Loi, 2022, NPJ breast cancer.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues

J. Lemonnier, J. Pierga, O. Couturier, 2019, EJNMMI Research.

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

I. Bièche, F. Clatot, F. André, 2022, Cancer Research.

Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

R. Gray, C. Sotiriou, S. Loi, 2019 .

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

J. Lemonnier, F. Bidard, J. Pierga, 2019, Angiogenesis.

Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial

I. Bièche, F. Clatot, J. Lemonnier, 2019, Annals of Oncology.

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study

S. Michiels, F. André, J. Lemonnier, 2020, Breast.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment

J. Lemonnier, M. Campone, O. Coqueret, 2019, Cell Death & Disease.

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

J. Lemonnier, J. Pierga, P. Viens, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

F. Penault-Llorca, F. André, J. Lemonnier, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)

F. Penault-Llorca, J. Lemonnier, F. Kwiatkowski, 2019, Breast.

Individualized Prediction of Menses Recovery After Chemotherapy for Early‐stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials

J. Lemonnier, M. Campone, B. Pistilli, 2019, Clinical breast cancer.

Baseline quality of life and chemotherapy toxicities in patients with early breast cancer

J. Lemonnier, S. Dauchy, T. Petit, 2023, Cancer.

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

J. Lemonnier, F. Bidard, M. Mouret-Reynier, 2020 .

PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.

J. Lemonnier, F. Bidard, B. Pistilli, 2018 .

Abstract PD2-06: CirculatingESR1mutation detection rate and early decrease under first line aromatase inhibitor and palbociclib in the PADA-1 trial (UCBG-GINECO)

I. Bièche, J. Lemonnier, F. Bidard, 2019, Poster Discussion Abstracts.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

S. Shak, F. Baehner, F. Penault-Llorca, 2018, BMC Cancer.

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

J. Lemonnier, B. Thürlimann, H. Hawle, 2023, JAMA oncology.

Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial.

J. Lemonnier, P. Pujol, J. Fricker, 2020 .

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2012, Familial Cancer.

Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway*

J. Lemonnier, O. Fromigué, P. Marie, 2001, The Journal of Biological Chemistry.

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

R. Gray, C. Sotiriou, S. Loi, 2022, npj Breast Cancer.

P4-20-01: Multicentric Phase II PACS 09/Beverly1 Trial: First Efficacy and Safety Results of Neoadjuvant Chemotherapy Combined with Bevacizumab in HER2−Negative Patients with Non-Metastatic Inflammatory Breast Cancer.

T. Delozier, F. André, J. Lemonnier, 2011 .